- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Pre-Enrollment
- Protocol: M23-699
- Drug: Upadacitinib
- Sponsor: Abbvie
- Description: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Enrollment Closed
- Protocol: CA42750
- Drug: OBINUTUZUMAB
- Sponsor: Roche
- Description: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
